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http://dx.doiabstractBACKGROUND: Spinal muscular atrophy is a rare genetic disease with devastating neurodegenerative consequences.
Timing of diagnosis is crucial for spinal muscular atrophy because early diagnosis may lead to early supportive care
and reduction in patient and caregiver stress. The purpose of this study was to examine the published literature for
diagnostic delay in spinal muscular atrophy. METHODS: A systematic literature search was conducted in the
PubMed and Web of Science databases for studies published between 2000 and 2014 that listed any type of spinal
muscular atrophy and without molecular, mouse, or pathology in the keywords. Mean and/or median age of onset
and diagnosis and delay in diagnosis was extracted or calculated. All estimates were weighted by the number of
patients and descriptive statistics are reported. RESULTS: A total of 21 studies were included in the ﬁnal analysis.
The weighted mean (standard deviation) ages of onset were 2.5 (0.6), 8.3 (1.6), and 39.0 (32.6) months for spinal
muscular atrophy types I, II, and III, respectively, and the weighted mean (standard deviation) ages of conﬁrmed
spinal muscular atrophy genetic diagnosis were 6.3 (2.2), 20.7 (2.6), and 50.3 (12.9) months, respectively, for types
I, II, and III. For studies reporting both age of onset and diagnosis, the weighted diagnostic delay was 3.6, 14.3, and
43.6 months for types I, II, and III, respectively. CONCLUSIONS: Diagnostic delay is common in spinal muscular at-
rophy. The length of delay varied by severity (type) of spinal muscular atrophy. Further studies evaluating this
delay and tools such as newborn screening are warranted to end the diagnostic delay in spinal muscular atrophy.
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Spinal muscular atrophy (SMA) is a neuromuscular dis-
ease that affects approximately 1 in 6000 to 1 in 11,000 live
births in the United States with a high carrier frequency of 1
in 40 to 60.1-4 SMA is an autosomal recessive disorder
caused by mutations in the survival motor neuron (SMN) 1
gene and is characterized by degeneration of the motor
neurons in the spinal cord, which results in progressive
muscular atrophy and weakness.1,3 It has been shown that
another gene, SMN2, codes for a protein similar to thatry:
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org/10.1016/j.pediatrneurol.2015.06.002encoded by the SMN1 gene andmultiple copies of SMN2 can
somewhat compensate for the loss of the SMN1 gene and
alleviate the severity of clinical symptoms observed.5,6
SMA is classiﬁed into several types based on the age of
onset of the disease and the degree of motor function
achieved by the affected individual.1,3 Approximately 50% of
patients diagnosed with SMA have type I, which has an
early onset; these infants usually do not survive beyond the
ﬁrst 2 years without intervention.1 Type I patients have the
most severe form of SMA with extensive muscle weakness,
are never able to sit without support, and have increasing
difﬁculty over time with swallowing and feeding, and res-
piratory difﬁculties.1,3 In type II SMA, the onset of symptoms
occurs slightly later than in type I and, although type II
children are generally able to sit without support and some
may stand, they are never able to walk independently. Type
II SMA patients can present with varying severity of bonender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 1.
Characteristics and Findings for Included Studies: Studies Reporting Means
Author, Year Country Type of Study SMA
Type
No. of
Patients
Sex Mean (SD)
Age
at First
Symptoms,
Months
Mean (SD)
Age at
Conﬁrmed
Diagnosis,
Months
Genetic Information
and SMN2 Copies
Reported
age of onset
only
Rudnik-
Schöneborn
et al., 200112,*
Poland,
Germany
Retrospective
chart review
with
questionnaire
survey
II 175 NR Normal sitters,
n ¼ 128: 6.6 (2.3)
Delay sitters,
n ¼ 47: 9.6 (2.7)
NR 57 type II and 186
type III patients
genetically
conﬁrmed
III 266 NR
Harada et al.,
20025
Japan Clinical
research
I 11 8 M, 3 F 3.3 (1.7) NR 1 copy ¼ 1 type I
patient; 2 copies ¼ 7
type I patients; 3
copies¼ 3 type I and
14 type II patients
and 1 type III patient
II 14 7 M, 7 F 9.2 (2.9)
III 1y 1 F 36
Cuscó et al.,
200313
Spain Clinical
research
I 1 1 F 1 NR 1 copy¼ 1 type I and
1 type II patient; 2
copies ¼ 2 type III
patients; 3
copies ¼ 2 type II
and 2 type III
patients
5 patients without
SMN1 deletion
excluded
II 3 2 M, 1 F 8.7 (5.5)
III 4 1 M, 3 F 46 (30.1)
Armand et al.,
200514
France Clinical
research
II 2 1 M, 1 F 12.5 (0.7) NR
Arkblad et al.,
200915
Sweden Clinical
research
I 15z 6 M, 13 F 1.9 (1.0) NR 2 copies ¼ all type I
patients; 3
copies ¼ 10 type II
and 4 type III
patients; 4
copies ¼ 1 type II
and 10 type III
patients
II 11 8 M, 3 F 8.7 (2.6)
III 14z 8 M, 7 F 55.0 (65.5)
Rudnik-
Schöneborn
et al., 200916
Germany Retrospective
chart review
with
questionnaire
survey
I 66 35 M, 31 F 1.4 (NR) NR 1 copy ¼ 4 patients;
2 copies ¼ 57
patients; 3
copies ¼ 5 patients
Sproule et al.,
201217
US Retrospective
chart review
I 28 14 M, 14 F 2.6 (1.4) NR
II 16 12 M, 4 F 7.0 (3.6)
Duman et al.,
201318
Turkey Retrospective
chart review
I 15 11 M, 4 F 3.7 (2.8) NR
Farrar et al.,
20138
Australia Clinical
research
I 20 11 M, 19 F 2.1 (2.2) NR Type II and III
patients average 2.7
copies (SD 0.6;
range 1-3).
II 31 16 M, 15 F 11.7 (4.1)
IIIa 14 6 M, 8 F 18.0 (5.4)
IIIb 5 1 M, 4 F 137.0 (26.0)
Reported age of conﬁrmed diagnosis only
Kinali et al.,
200419
UK Clinical
research
II 4 2 M, 2 F NR 19.5 (4.0)
III 8 5 M, 3 F 49.8 (16.7)
van Bruggen
et al., 201120
The
Netherlands
Clinical
research
II 11x 4 M, 7 F NR 13.1 (6.0)
Fujak et al.,
201321
Germany Clinical
research
II 99 65 M, 61 F NR 19.2 (10.8) 47 patients were not
genetically
conﬁrmed
III 27 37.2 (18.0)
Finkel et al.,
201422
US Clinical
research
I 7 NR NR 2.8 (2.0)
Reported both age of onset and age of conﬁrmed diagnosis
Oskoui
et al., 200723
North
America
and
other
countries
Registry
review
I 143 72 M, 71 F 2.5 (1.7) 4.6 (2.9) 42 patients were not
genetically
conﬁrmed
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TABLE 1. (continued )
Author, Year Country Type of Study SMA
Type
No. of
Patients
Sex Mean (SD)
Age
at First
Symptoms,
Months
Mean (SD)
Age at
Conﬁrmed
Diagnosis,
Months
Genetic Information
and SMN2 Copies
Park et al.,
201024
Korea Retrospective
chart review
I 14 8 M, 6 F 3.4 (1.6) 4.3 (1.4) 1 patient was not
genetically
conﬁrmed
Ge et al.,
201225
China Retrospective
chart and
registry review
with
questionnaire
survey
I 107 61 M, 46 F 3.1 (2.7) 9.0 (12.8)
II 105 62 M, 43 F 8.7 (3.8) 23.0 (15.0)
III 25 17 M, 8 F 21.1 (11.7) 64.7 (49.3)
Abbreviations:
F ¼ Female
M ¼ Male
NR ¼ Not reported
SD ¼ Standard deviation
SMN ¼ Survival motor neuron
* Included in both Tables 1 and 2 because the study reported mean age of onset for type II patients and median age of onset for part of type III patients.
y Excluded one adult-onset patient.
z Number of patients based on participants’ reported age of onset and/or diagnosis.
x Excluded one prenatally diagnosed patient.
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chewing, and respiratory problems.1 The survival rate of
type II patients is higher than type I.7,8 Patients with type III
SMA have less severe symptoms and are able to walk and
reach the major motor milestones, but often lose the ability
to walk over time as the disease progresses.1,9 These pa-
tients then need wheelchairs and may develop scoliosis,
obesity, and other problems related to lack of mobility.1,9
Because symptoms for type III SMA appear later in child-
hood, type III is generally diagnosed later than type I or type
II SMA.1,3 The type IV SMA category includes those patients
with mild disease and who are diagnosed in early adult-
hood (age 18 years).1
Although awareness of SMA is increasing, diagnostic
delay is common as SMA symptoms can vary widely in
onset and severity and can resemble other diseases.10 This
alsomay be due to the potential lack of expertise in this area
for many health care professionals who may often rule out
other diagnoses before considering SMA. Data on the fre-
quency and extent of the diagnostic delay in SMA are
limited. The objective of this systematic review was to
evaluate the diagnostic delay in SMA and to identify po-
tential factors for this delay based on the published
literature.
Materials and Methods
A systematic review of the literature was conducted using the
PubMed and Web of Science databases. Articles in English that were
published between January 1, 2000, and August 21, 2014, were identiﬁed
using the search terms: (“spinal muscular atrophy” OR “Werdnig-Hoff-
mann”) AND (“type 1” OR “type I” OR infantile) NOT (pathology OR
molecular OR mouse OR mice) for SMA type I; and “spinal muscular
atrophy” AND (“type 2” OR “type II” OR “type 3” OR “type III”) NOT
(pathology* OR molecule* OR mouse OR mice) for SMA types II and III.
This time frame was chosen because the genetic test for SMN1 became
available in the late 1990s.11 Included in the analysis were articles thatreported age of ﬁrst symptom onset and/or age of conﬁrmed SMA ge-
netic diagnosis. Studies with a prenatal SMA diagnosis, no conﬁrmed
genetic case, or adult onset patients (18 years of age) and publications
of case reports or case series were excluded.
Age of symptom onset, age of diagnosis as conﬁrmed by genetic
testing, and diagnostic delay were evaluated across studies. Age of onset
was deﬁned as the age of the patient when the ﬁrst symptom was
observed as reported by parents or caregivers using questionnaires or
collected from medical charts in chart review studies. The age of diag-
nosis was deﬁned as the age of the patient when SMA diagnosis was
conﬁrmed with genetic testing. Diagnostic delay was deﬁned as the time
between the age of onset and age of conﬁrmed diagnosis and was
calculated directly if both age of onset and diagnosis were reported in the
same study. The mean and standard deviation (SD) of age of onset,
conﬁrmed diagnosis, and diagnostic delay for studies that reportedmean
ages were weighted by the number of patients in each study. The weight
for each study was the proportion of patients in that study among all
patients with the available age information. For example, the weight for
Harada et al.5 applied in the weighted mean age of onset calculation for
type I was 11 (number of patients in Harada et al.5; Table 1) divided by
the total number of patients. Theweightedmean agewas then calculated
as the sum of the product of ages reported in the study and the associ-
ated weights for the study. For studies that only reported median ages,
the range of the medians was extracted. If both median and mean were
reported, the mean was used in the analysis. As a sensitivity analysis,
studies that reported median ages were analyzed and reported
separately. An analysis of potential overlap in study populations in
publications using the same dataset also was conducted. Age of onset
and diagnosis also were examined by type of SMA, region (North
America, Europe, and Asia Paciﬁc), and year of publication.Results
The initial search and screening by title resulted in 355
publications (Fig 1). After reviewing the abstract, 204 pub-
lications were excluded because they did not meet the
search criteria. The remaining 151 publications were
reviewed in detail and an additional 130 were excluded
because they did not meet the inclusion criteria. After
Number of studies, n = 355
PubMed and Web of Science search with following criteria:
•  Written in English
•  Published between January 1, 2000 and August 21, 2014
•  Keywords: SMA, Werdnig-Hoffmann, infantile, type 1, 2, 3 or I, II, III
•  Excluded keywords: pathology, molecular, and mouse/mice
n = 151
Selected to review in detail based on abstract reviews
n = 204
Excluded based on review of abstracts
n = 16
Mean ages available
n = 5
Only median ages 
available
n = 21
Included in the analysis with information from either 
age of onset or genetically confirmed SMA diagnosis
n = 130
Excluded due to:
•  No age of onset or diagnosis, n = 86
•  Not genetically confirmed cases, n = 24
•  Prenatal diagnosis, n = 2
•  Age of onset after 18 years old, n = 3
•  Case report/case series studies, n = 15
FIGURE 1.
Selection of studies for review. SMA, spinal muscular atrophy.
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only adult onset patients, a total of 21 publications were
included in the ﬁnal analysis (Tables 1 and 2, Fig 1). Of these,
11 articles reported only age of onset, ﬁve reported only age
of conﬁrmed diagnosis, and ﬁve reported both age of onset
and conﬁrmed diagnosis (Tables 1 and 2). Although some
publications included mean age information on more than
one type of SMA, 11 articles studied SMA type I, 11 studied
SMA type II, and 7 studied SMA type III (Table 3). Evaluation
of potential overlap in patients from publications reporting
data from the same dataset revealed no double counting of
patients in the studies. Clinical research studies were the
most common type of study (12; 57.1%), followed by
retrospective chart review and registry review (six; 28.6%),
and retrospective chart review with questionnaire survey
(three; 14.3%). Six studies were conducted in North
America, eight in Europe, ﬁve in Asia, one in Turkey, and one
in Australia (Tables 1 and 2).
The weighted mean  SD age of onset was
2.5  0.6 months (range 1.0-11.0 months; number of
patients, n ¼ 420) for SMA type I, 8.3  1.6 months (range
2.0-18.0 months; n ¼ 357) for SMA type II, and
39.0  32.6 months (range 5.0-192.0 months; n ¼ 63)
for SMA type III (Table 4, Fig 2). Weighted mean  SD age
of conﬁrmed diagnosis was 6.3  2.2 months (range
0.6-9.0 months; n ¼ 271), 20.7  2.6 months (range
1.2-72.0 months; n ¼ 219), and 50.3  12.9 months (range
3.0-82.8 months; n ¼ 63) for SMA types I, II, and III,
respectively (Table 4, Fig 2).
For the subset of studies that reported both age of onset
and age of diagnosis, SMA type III patients had the longest
delay (43.6 months; n ¼ 25), followed by type II
(14.3 months; n ¼ 105), and type I had the shortest delay in
diagnosis (3.6 months; n¼ 264; Table 4). For SMA type I, the
difference between the weighted mean age of conﬁrmeddiagnosis (6.3 months) and the weighted mean age of onset
(2.5 months) was 3.8 months, which was similar to the
diagnostic delay measured in the subset of studies that
included both age of conﬁrmed diagnosis and mean age of
onset (3.6 months; Table 4). Similarly, for SMA type II, the
difference of 12.4 months was comparable to the delay in
diagnosis observed in the subset of studies that included
both age of conﬁrmed diagnosis and mean age of onset
(14.3 months). However, in SMA type III the difference be-
tween mean age and age of onset was 11.3 months versus
43.6 months from studies that evaluated both of these
outcomes. In the studies that reported onlymedians (n¼ 6),
the range of reported median age of onset was
1.2-3.0 months for SMA type I, 7.5-15.0 months for type II,
and 8.0-24.0months for type III (Table 5). Themedian age of
diagnosis was 2.3-6.0 months for SMA type I,
11.5-13.2 months for type II, and 42.0 months for type III
(Table 5).
A subgroup analysis by region (data not shown) indi-
cated that patients in North America appeared to have been
diagnosed earlier than those in Europe or the Asia Paciﬁc
region. The weighted mean age of onset was greatest for
SMA type III in North America compared with those in
Europe and the Asia Paciﬁc region. An analysis of delay in
diagnosis by year of publication did not show any clear
trends (data not shown). A further analysis of age of onset
by SMN2 copy number also was inconclusive due to the
small number of studies (n ¼ 3) reporting SMN2 copy
numbers and mean age of diagnosis (data not shown).
Discussion
This is the ﬁrst extensive systematic literature review to
study the diagnostic delay in SMA. Our review included a
wide range of studies from several regions and our results
TABLE 2.
Characteristics and Findings for Included Studies: Studies Reporting Medians
Author, Year Country Type of Study SMA
Type
No. of
Patients
Sex Median (range)
Age at First
Symptoms,
Months
Median (range)
Age at Conﬁrmed
Diagnosis, Months
Genetic Test Information
and SMN2 Copies
Reported age
of onset only
Rudnik-
Schöneborn
et al., 200112,*
Poland,
Germany
Retrospective
chart
review with
questionnaire
survey
II 175 NR NA NR 57 type II and 186 type III
patients genetically
conﬁrmed
III 266 8 for delayed
walking
(walked after
18 month
of age, n ¼ 27)
Arai et al.,
200526
Japan Clinical
research
I 7 5 M, 2 F 2 (1-7) NR 1 type I and 1 type II patient
not genetically conﬁrmedII 2 1 M, 1 F 11.3 (7-16)
III 1 1 F 15
Yuan et al.,
201427
China Retrospective
chart review
I 52 29 M, 23 F 1.2 (0-6) NR 96/132 patients had genetic
test; among these: 34/35 of
type I, 30/32 of type II, and
23/29 of type III patients
had SMN1 deletion
II 46 26 M, 20 F 12 (0-18)
III 34 16 M, 18 F 23.5 (18-156)
Reported age of conﬁrmed diagnosis only
Lemoine et al.,
201228
US Retrospective
chart review
I 49 29 M, 20 F NR Proactive respiratory
care group, median:
4.5 (IQR 1.8-6.5)
Supportive respiratory
care group, median: 2.3
(IQR 1.3-4.8)
2 copies ¼ 48 patients
Reported both age of onset and age of conﬁrmed diagnosis
Kaufmann
et al., 20129
US Clinical
research
II 41 16 M, 25 F 9.6 (IQR 6-12) 13.2 (IQR 10.8-16.8) 3 copies ¼ 41 type II and
20 type III patients;
4 copies ¼ 17 type
III patients; 5 copies ¼ 1
type III patient
III 38 21 M, 17 F 24 (IQR 12-36) 42 (IQR 30-68.4)
Finkel et al.,
20147
US Clinical
research
I 34 19 M, 15 F 3 (IQR 2-4) 6 (IQR 4-7) 2 copies ¼ 23 type I and
2 type II patients;
3 copies ¼ 9 type I and
43 type II patients
II 45 18 M, 27 F IIa: 11.0
(IQR 7-12)
IIb: 8.5
(IQR 6-12)
IIa: 11.5 (IQR 9-14)
IIb: 13.0 (IQR 10-18)
Abbreviations:
F ¼ Female
IQR ¼ Interquartile range
M ¼ Male
NA ¼ Not applicable
NR ¼ Not reported
SD ¼ Standard deviation
SMN ¼ Survival motor neuron
* Included in both Tables 1 and 2 because the study reported mean age of onset for type II patients and median age of onset for part of type III patients.
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patient with SMA shows symptoms to when the diagnosis
is conﬁrmed. From the results of this review, the only
factor directly related to the length of delay in diagnosis
was the type of SMA. The shortest delay in diagnosis was
observed for SMA type I patients and the longest delay was
for type III patients, indicating that severity of disease has
an impact on time to diagnosis. Although we analyzed
delay of diagnosis by geographic region and year of study
publication, we did not ﬁnd a clear correlation between
delay in diagnosis and these factors, likely due to the small
sample size.
It has been noted that the delays in diagnosis of SMA
resulted from patient visits to multiple health care pro-
fessionals to rule out the possibility of other illnesses before
genetic testing for SMA was performed and a conﬁrmed
diagnosis was obtained.10 This “diagnostic odyssey” fromthe time ﬁrst symptoms are noticed to a conﬁrmed genetic
diagnosis of SMA puts patients and caregivers through
physical and mental stress.10 Although it is not clear what
kind of functional loss occurs during the delay, a later
diagnosis may result in a missed opportunity for optimal
early intervention for SMA. Early diagnosis and care of SMA
also can lead to lower patient and caregiver burden;
therefore, tools for improving the appropriate and early
detection of SMA, such as newborn screening, may be
warranted.29-31 Regular newborn screening is currently not
standard practice in the United States, although the SMA-
determining gene was identiﬁed in 1995 and the test is
available.11,31,32 The idea of newborn screening has a high
level of support among parents of children who have SMA
and among expecting parents.33,34
A long delay to diagnosis has been noted in other pedi-
atric diseases as well. For example, a median delay of
TABLE 3.
Studies Evaluated by SMA Type and Type of Study
Type I Type II Type III
SMA type*
Total no. of studies included in the analysis 11 11 7
No. of studies only reporting age of onset 7 7 4
No. of studies only reporting age of conﬁrmed diagnosis 1 3 2
No. of studies reporting both age of onset and age of conﬁrmed diagnosis 3 1 1
Type of study*
Retrospective chart review and registry review 4 1 0
Retrospective chart review with questionnaire survey 2 2 1
Clinical research 5 8 6
Abbreviation:
SMA ¼ Spinal muscular atrophy
* Numbers are not mutually exclusive because one study could have reported on more than one type of SMA. Only studies with mean ages available are included (Table 1).
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has been noted in patients with Pompe disease,35 whereas a
delay of 6 months to more than 4 years has been docu-
mented in patients with Duchenne muscular dystrophy.36 It
is important to identify ways to reduce these delays to
diagnosis for all pediatric diseases to provide earlier inter-
vention for disease management or appropriate treatment.
As shown in other childhood diseases,35 earlier treatment
has been associated with better outcomes and suggests that
in a neurodegenerative condition such as SMA, an earlier
diagnosis, particularly for type I and II patients, will be
immensely helpful to increase the chance of survival using
optimal care and supportive interventions.
A strength of this study is the application of stringent
criteria by including only those publications that based
diagnosis on conﬁrmed genetic testing and excluding anyTABLE 4.
Weighted Mean Age of Onset, Conﬁrmed Diagnosis, and Diagnostic Delay* in SMA
Type I Type II Type III
Age of onset, months
No. of patients for
weighted mean
420 357 63
No. of studies for
weighted mean
10 8 5
Mean (SD) 2.5 (0.6) 8.3 (1.6) 39.0 (32.6)
Range 1.0-11.0 2.0-18.0 5.0-192.0
Age of conﬁrmed diagnosis, months
No. of patients for
weighted mean
271 219 60
No. of studies for
weighted mean
4 4 3
Mean (SD) 6.3 (2.2) 20.7 (2.6) 50.3 (12.9)
Range 0.6-9.0 1.2-72.0 3.0-82.8
Delay in diagnosis, months
No. of patients for
weighted mean
264 105 25
No. of studies for
weighted mean
3 1 1
Mean (SD) 3.6 (1.9) 14.3 (0.0) 43.6 (0.0)
Range 1.0-5.9 14.3y 43.6y
Abbreviations:
SD ¼ Standard deviation
SMA ¼ Spinal muscular atrophy
* Case reports and studies reporting only median age were excluded; data
weighted by total number of patients evaluated in studies that met the search
criteria.
y Reported in only one study.case studies or case series. These criteria allowed us to
obtain robust estimates (i.e., less affected by special cases in
case report studies) for patients that were properly diag-
nosed with current technology, such as genetic testing.
Moreover, the weighted mean age of onset and weighted
mean age of diagnosis appeared to match between studies
that reported only the age of onset or age of conﬁrmed
diagnosis and those that reported both age of onset and
conﬁrmed diagnosis, which indicates the validity of the
ﬁndings. However, this study has a few limitations. The
number of publications evaluated overall is small, and of
these only a few focused on SMA type III; therefore, it is
difﬁcult to draw any conclusions for type III. Also, the age of
onset may be affected by parental recall bias and could be
more common in SMA type III patients because of the
longer diagnostic delay. Therefore, more studies on age of
onset and diagnosis of SMA, particularly type III, are needed
to provide a reliable estimate of the diagnostic delay in
these patients.Conclusions
This systematic review clearly indicates that there is a
delay in diagnosis of SMA and that the length of delay varies
by the severity (type) of SMA. Based on the publications
examined for this review, it is difﬁcult to conclude if other
factors are related to the delay. Newborn screening, which
has resulted in improved outcomes for pediatric patients 
50.3 
20.7 
6.3 
39.0 
8.3 
2.5 
0 10 20 30 40 50 60
Type III
Type II
Type I
Weighted Mean Age, Months
Age of onset
Age of diagnosis
FIGURE 2.
Age of onset and diagnoses by type of SMA. SMA, spinal muscular atrophy.
(The color version of this ﬁgure is available in the online edition.)
TABLE 5.
Range of Median Age of Onset, Diagnosis, and Diagnostic Delay in SMA
Type I Type II Type III
Age of onset, months
No. of studies 3 5 3
No. of patients 93 134 99
Range of reported median, 1.2-3.0 7.5-15.0 8.0-24.0
Age of diagnosis, months
No. of studies 2 2 1
No. of patients 83 86 38
Range of reported median 2.3-6.0 11.5-13.2 42.0*
Abbreviations:
SD ¼ Standard deviation
SMA ¼ Spinal muscular atrophy
* Reported in only one study.
C.-W. Lin et al. / Pediatric Neurology 53 (2015) 293e300 299with other diseases such as cystic ﬁbrosis,30 may provide an
opportunity for earlier diagnosis of SMA and could be the
most effective solution to end this SMA diagnostic odyssey.
Future studies are necessary to conﬁrm the observations in
this report, to examine the extent of functional decline
during the prediagnosis period, and to evaluate the
potential negative impact the process of obtaining an
appropriate diagnosis has on patients and families of
patients with SMA.
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